Vanda Pharmaceuticals
VNDA
109 hedge funds and large institutions have $682M invested in Vanda Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 44 increasing their positions, 26 reducing their positions, and 14 closing their positions.
139% more call options, than puts
Call options by funds: $32.6M | Put options by funds: $13.6M
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
69% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 26
59% more capital invested
Capital invested by funds: $428M → $682M (+$254M)
8% more funds holding
Funds holding: 101 → 109 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$23.3M |
| 2 |
Morgan Stanley
New York
|
+$8.62M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$7.76M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$5.96M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
Signpost Capital Advisors
New York
|
-$8.82M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$8.23M |
| 3 |
Goldman Sachs
New York
|
-$6.51M |
| 4 |
Bank of New York Mellon
New York
|
-$5.2M |
| 5 |
JG
Jefferies Group
New York
|
-$2.67M |
VNDA Hedge Fund Activity: Q4 2014 in Review
109 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2014, worth a combined $682M — up 59% from $428M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new VNDA positions and 14 closed out — a net gain of 11 holders — while 44 added to existing stakes and 26 trimmed.
The largest buyer was Deerfield Management, adding an estimated $23.3M. The largest seller was Signpost Capital Advisors, cutting an estimated $8.82M.
- 109 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2014, up from 101 in Q3 2014.
- Funds reported $682M of Vanda Pharmaceuticals stock for Q4 2014, up 59% quarter-over-quarter.
- 25 funds opened new Vanda Pharmaceuticals positions in Q4 2014 and 14 closed out, a net change of +11 holders.
- The largest Vanda Pharmaceuticals buyer in Q4 2014 was Deerfield Management, an estimated $23.3M added.
- The largest Vanda Pharmaceuticals seller in Q4 2014 was Signpost Capital Advisors, an estimated $8.82M sold.
Based on aggregated 13F filings for Q4 2014.